Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma TranscriptSeeking Alpha • 10/24/25
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell CarcinomaBusiness Wire • 10/24/25
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell CarcinomaBusiness Wire • 10/21/25
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBusiness Wire • 10/14/25
Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?Zacks Investment Research • 09/18/25
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 05/01/25
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel DiseaseBusiness Wire • 04/29/25
20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'Market Watch • 02/18/25
Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 02/06/25